Colin Sperring

Damian’s up next!

Incredibly grateful and excited to be joining the @ColumbiaNeuro team. Thank you Dr. Jeffrey Bruce, @PCanoll , @MateiBanu, @MikeArgenziano, @ColumbiaNeuro, @CUBrainTumorLab for the incredible mentorship and support!

#OnlineFirst: Single-cell analysis of 5-aminolevulinic acid intraoperative labeling specificity for glioblastoma. thejns.org/view/journals/….

No-Reflow Post-Recanalization in Acute Ischemic Stroke: Mechanisms, Measurements, and Molecular Markers | Stroke ahajournals.org/doi/10.1161/ST…

Outstanding talk by ⁦@MikeArgenziano⁩ at #AANS2023 presenting our work on #GBM and #ferroptosis demonstrating how we can target resistant cancer cells. Learning from clinical trials to advance therapy! So proud of Michael, physician scientist superstar!

Excited that our new paper in @NatureComms is also highlighted in PNAS journal club @PCanoll @bstockwell pnas.org/post/journal-c…

Really happy to share our new paper published in @NatureComms, an amazing collaboration with @bstockwell lab and others, demonstrating that cysteine/methionine deprivation can sensitize glioma cells to a form of cell death called ferroptosis nature.com/articles/s4146…

Check out our new preprint! A study led by @MateiBanu, PGY7 @ColumbiaNeuro. We find that astrocytic-like quiescent #glioma cells are driven by distinct metabolic programs, and this treatment-resistant glioma subpop can be effectively targeted via #ferroptosis in human GBM tissue.